Clioquinol topical Disease Interactions

The use of oral clioquinol (no longer marketed in the U.S.), generally at high dosages for prolonged periods, has resulted in ocular and neurologic toxicity, including optic neuritis, optic atrophy, and subacute myelo-optic neuropathy. Because the drug is systemically absorbed following topical administration to the skin, therapy with topical clioquinol should be administered cautiously in patients with peripheral neuropathy, optic neuritis, or preexisting visual defects. The use of occlusive dressings may substantially increase percutaneous absorption and should be avoided. All patients should be advised to immediately discontinue the drug and contact a physician if visual disturbances occur or are exacerbated during therapy. Clioquinol is not recommended for use in children and is contraindicated for those under 2 years of age.

Percutaneous absorption of clioquinol topical occurs. Protein-bound serum iodine levels may be increased during treatment with clioquinol topical and may interfere with certain thyroid function tests. Therapy with clioquinol topical should be used cautiously in patients with thyroid dysfunction.